Neurocrine Biosciences and Diurnal Ltd. showcased their neuroendocrinology pipeline at ENDO 2024, featuring primary data from Phase 3 studies of crinecerfont for congenital adrenal hyperplasia. Results were recently published in The New England Journal of Medicine.